Bleeding risks associated with vitamin K antagonists.

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Vitamin K antagonists (VKAs) are essential anticoagulants for preventing thromboembolic events like stroke and myocardial infarction.
• Major bleeding is the most common adverse event associated with VKA therapy, occurring in 1-3% of patients annually.
• Assessing the benefit-risk balance of anticoagulation requires awareness of bleeding risk factors.

Purpose of the Study:

• To review the incidence of major bleeding in patients on VKA therapy.
• To discuss established and emerging risk factors for bleeding during anticoagulation.
• To outline clinical prediction rules for assessing bleeding risk.

Main Methods:

• This is a narrative review.
• Literature search on Vitamin K antagonist therapy, major bleeding incidence, risk factors, and prediction rules.
• Synthesis of current evidence on bleeding risk in anticoagulated patients.

Main Results:

• Major bleeding occurs in 1-3% of patients on long-term VKA therapy annually.
• Numerous patient-specific and treatment-related factors increase bleeding risk.
• Several clinical prediction rules exist to stratify bleeding risk.

Conclusions:

• Effective VKA anticoagulation requires careful consideration of individual bleeding risk.
• Awareness of risk factors and utilization of prediction tools can optimize patient safety.
• Further research may refine risk stratification and management strategies.